Siegfried Aktie
1 106,00CHF | 10,00CHF | 0,91% |
WKN: 891169 / ISIN: CH0014284498
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 79,82 |
Ernst Göhner Stiftung | 5,01 |
Interogo Foundation | 4,97 |
Siegfried Holding AG | 4,96 |
Zürcher Kantonalbank (Investment Management) | 2,95 |
Credit Suisse Asset Management (Schweiz) AG | 2,87 |
Braginsky Family | 2,84 |
Government Pension Fund - Global (The) | 2,51 |
DFA International Small Cap Value Portfolio | 1,30 |
Vanguard Total International Stock Index Fund | 1,27 |
Coeli SICAV I - Global Select Fund | 0,98 |
Vanguard Developed Markets Index Fund | 0,78 |
Marianne Späne | 0,74 |
Wolfgang Wienand, PhD | 0,63 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 2 300 | 2 500 | 3 637 | 3 680 | 3 800 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,36 | 0,34 | 0,30 | 0,33 | 0,33 |
Bilanz (in Mio. CHF) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 590 | 651 | 826 | 945 | 983 |
Summe Anlagevermögen | 579 | 591 | 843 | 848 | 878 |
Summe Aktiva | 1 169 | 1 242 | 1 669 | 1 793 | 1 862 |
Bilanz (in Mio. CHF) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 391 | 377 | 560 | 590 | 525 |
Summe Fremdkapital | 733 | 747 | 1 061 | 1 082 | 1 103 |
Summe Eigenkapital | 436 | 496 | 608 | 711 | 758 |
Summe Passiva | 1 169 | 1 242 | 1 669 | 1 793 | 1 862 |
Adresse
Untere Brühlstrasse 4, 4800 Zofingen | |
Telefon | +41 (62) 746-11-11 |
Internet | http://www.siegfried.ch |
Management
Alexandra Brand
Independent Non-Executive Director |
Andreas Casutt
Chairman |
Beat Walti
Independent Non-Executive Director |
Christa Brügger
Senior Manager-Communications |
Elodie Carr-Cingari
Independent Non-Executive Member |
Irene Wosgien
Chief Human Resources Officer |
Isabelle Welton
Independent Non-Executive Director |
Jürgen Roos
Chief Scientific Officer |
Klaus Stingl
Global Head-Business Development |
Marcel Imwinkelried
Chief Executive Officer |
Marianne Späne
Chief Business Officer-Drug Substances & Products |
Martin Schmid
Vice Chairman |
Reto Suter
Chief Financial Officer |
Wolfram Carius
Independent Non-Executive Director |